GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIC:REGN-RM) » Definitions » Shiller PE Ratio

Regeneron Pharmaceuticals (MIC:REGN-RM) Shiller PE Ratio : (As of Jul. 20, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Regeneron Pharmaceuticals Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regeneron Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Regeneron Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Shiller PE Ratio Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.17 32.61 30.55 32.06 22.53

Regeneron Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.84 35.34 34.02 22.53 19.41

Competitive Comparison of Regeneron Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Shiller PE Ratio falls into.


;
;

Regeneron Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Regeneron Pharmaceuticals's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Regeneron Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=600.646/134.9266*134.9266
=600.646

Current CPI (Mar. 2025) = 134.9266.

Regeneron Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201506 94.050 100.684 126.037
201509 119.592 100.392 160.732
201512 98.128 99.792 132.676
201603 107.611 100.470 144.516
201606 107.847 101.688 143.099
201609 143.192 101.861 189.674
201612 132.147 101.863 175.041
201703 120.926 102.862 158.621
201706 198.463 103.349 259.102
201709 192.194 104.136 249.022
201712 86.353 104.011 112.020
201803 238.177 105.290 305.220
201806 302.859 106.317 384.358
201809 338.821 106.507 429.231
201812 497.077 105.998 632.738
201903 258.986 107.251 325.818
201906 105.936 108.070 132.263
201909 369.516 108.329 460.240
201912 429.460 108.420 534.454
202003 432.169 108.902 535.448
202006 532.495 108.767 660.564
202009 583.552 109.815 716.995
202012 763.105 109.897 936.908
202103 765.871 111.754 924.674
202106 2,055.907 114.631 2,419.900
202109 1,047.120 115.734 1,220.765
202112 1,455.780 117.630 1,669.849
202203 903.822 121.301 1,005.347
202206 470.580 125.017 507.882
202209 703.063 125.227 757.523
202212 642.600 125.222 692.402
202303 539.481 127.348 571.587
202306 689.851 128.729 723.065
202309 857.218 129.860 890.667
202312 919.444 129.419 958.569
202403 573.711 131.776 587.427
202406 1,121.864 132.554 1,141.946
202409 1,045.812 133.029 1,060.731
202412 867.264 133.157 878.789
202503 600.646 134.927 600.646

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regeneron Pharmaceuticals  (MIC:REGN-RM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Regeneron Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines